Hemispherx (HEB) Updates on FDA Panel Vote for Ampligen; Fails to Win Backing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Hemispherx Biopharma (HEB) Investors Go For Ride Following FDA Panel Vote
December 20, 2012 5:34 PM ESTHemispherx Biopharma, Inc. (NYSE: HEB) saw heavy action on Thursday after news broke that its Ampligen drug was not proven effective in treatment for chronic fatigue. An FDA panel voted 9-4 against the efficacy of the drug. Several members cited need for additional... More
Hemispherx (HEB) fails to win FDA panel backing for Ampligen efficacy
December 20, 2012 4:29 PM ESTHemispherx Biopharma, Inc. (NYSE: HEB) fails to win FDA panel backing for Ampligen efficacy.... More
